Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: omecamtiv mecarbil, mavacamten, danicamtiv | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 191 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 14055
Sealed predictions
- MYL3 in dopamine neurons, braak-0.40 (p 0.285) → -0.26 (p 0.499)receipt 14062
Swarm cases
receipt 14062: MYL3 in dopamine neurons, braak
- power
- full sample -0.38 (p 0.116, n 18), 95% CI -0.72 to +0.10. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.37 (p 0.132, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.49 (p 0.037, n 18). not the mix.
- skeptic
- leave-one-out range -0.55 to -0.31, sign flips 0; without severely affected donors -0.38 (p 0.116, n 18). fragile.
- cell type
- strongest in astrocytes: -0.61 (p 0.0069, n 18) vs -0.38 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MYL3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MYL3 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.28 p 0.328 (needs p < 1.6e-4)
Receipts
loading the receipts